IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
Viibryd
From:
Sylvia Caras <[log in to unmask]>
Reply To:
[log in to unmask]
Date:
Tue, 25 Jan 2011 09:12:15 -0800
Content-Type:
text/plain
Parts/Attachments:
text/plain (13 lines) 
FDA Approves Viibryd to Treat Major Depressive Disorder

 From the PharmaLive.com News Archive - Jan. 21, 2011

The FDA today approved Viibryd tablets (vilazodone hydrochloride) to 
treat major depressive disorder in adults. The most frequent adverse 
reactions reported by patients taking Viibryd in clinical trials 
included diarrhea, nausea, vomiting, and insomnia. The drug will be 
available in 10, 20 and 40 milligram tablets.


"People Who experience mood swings, fear, voices and visions"

ATOM RSS1 RSS2